-5%
Flibanserin is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This condition is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not caused by a coexisting medical or psychiatric condition, problems within the relationship, or the effects of medication or other drug substances.
Fevigra is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This condition is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of medication or other drug substances. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire, and generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation, or partner.
The recommended dosage of Fevigra is 100 mg orally once per day at bedtime. It’s administered at bedtime to mitigate the risks of hypotension, syncope, accidental injury, and central nervous system (CNS) depression. If a dose is missed at bedtime, the next dose should be taken at bedtime the following day without doubling.
Special precautions should be taken when coadministering flibanserin with alcohol or moderate to strong CYP3A4 inhibitors due to the risk of severe hypotension and syncope. CNS depression, including somnolence and sedation, can occur, especially if taken during waking hours or with alcohol or other CNS depressants. Breastfeeding is not recommended during treatment due to potential serious adverse reactions in the breastfed infant.